|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's range||73.80 - 75.56|
|52-week range||15.30 - 189.89|
|Beta (5Y monthly)||1.51|
|PE ratio (TTM)||4.72|
|Earnings date||02 Aug 2021 - 06 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||87.00|
Teladoc (NYSE: TDOC) and Fulgent Genetics (NASDAQ: FLGT) are significantly off their highs but have booming businesses that will eventually catch up with their stock prices. Overall growth was 151%, with 69% attributable to the legacy business -- without acquisitions. The stock is nearly 50% off its all-time high as investors fret over slowing member growth and concerns that the need for virtual visits will collapse as cases of COVID-19 disappear.
Legendary investor Benjamin Graham, a mentor of Warren Buffett, is thought to have originated the idea of "special situation" investments. In his classic book the Intelligent Investor, Graham discussed how there can be mispricing between assets and markets. Fulgent Genetics (NASDAQ: FLGT) may have found itself in a very special situation where the market is mispricing the core assets of the company due to the cloud of uncertainty surrounding COVID testing.
In this video from Motley Fool Live, recorded on May 10, Fool.com contributors Brian Orelli and Keith Speights discuss how long that benefit could last and how investors should value the company accordingly. Brian Orelli: The number of COVID-19 tests performed in the U.S. has been dropping precipitously. Speights: No. That's what Fulgent did in Q1.